NCT00204594View on ClinicalTrials.gov

Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Malignant Melanoma
Interventions
DRUG

rM28

DRUG

autologous PBMCs

Trial Locations (1)

72076

University of Tuebingen, Department of dermatology, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER

NCT00204594 - Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28 | Biotech Hunter | Biotech Hunter